Faculty

Institution

Unit

Venue

Pariya Sukhumalchandra

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hematopoietic Biology And Malignancy

NonePariya Sukhumalchandra is currently serving as a Hematopoietic Biology And Malignancy faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Pariya Sukhumalchandra

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

immunology immunotherapy cell biology cancer immunotherapy cellular therapy cancer cells immune responses leukemia tumor biology hematology oncology immunomodulation medicinal research hematological malignancies pharmacology cellular immune responses immune checkpoint inhibitors antigen processing cancer biology cancer research cell research cancer treatment cancer immunosurveillance dermatology cell transplantation oncogenes peptides cell therapy tumor targeting acute myeloid leukemia clinical research cancer care experimental medicine hla typing molecular immunology clinical immunology peptide therapeutics myeloid neoplasia breast cancer cells peptide science reproductive immunology adult t-cell leukemia-lymphoma antibody engineering clinical transplantation cellular biochemistry cell-matrix interactions innate immune system skin cancer histocompatibility t-regulatory cell malignant blood disorders pr1-targeted immunotherapy metastatic melanoma novel subset cyclin e medical mycology clinical investigation tumor suppressors lymphoid neoplasia therapeutic vaccines melanoma single-cell analysis immunoediting stem-cell therapy stem cell transplantation clinical mycology adoptive t-cell therapy primary human aml broad cross-presentation solid tumors leads cathepsin g is acute lymphoblastic leukemia potential immunotherapeutic target tumor cells immunotherapeutic targets bi-specific antibody

Notable Scholarly Works

Notable Federal Grants

Collaborators

Immunotherapy Targeting a Leader Sequence Cathepsin G-Derived Peptide. Leukemia (2025)

immune responsescellular therapyimmunotherapypeptide therapeuticsimmunologypeptide sciencepeptidesmedicinal researchleader sequence

T Cell Receptor Mimic Car T Cells Targeting Cathepsin G Signal Peptide. Leukemia (2025)

receptorsimmune responsescellular therapycell biologycell signalingmolecular immunologyimmunologycell researchsignal transductioncellular immune responses

A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. Blood (2024)

Gheath AlatrashCristina KnapeLaura WhitedDawen SuiCara L HaymakerJason YehMegan MarcotulliPariya SukhumalchandraLisa St. JohnHsinyi LuDaniela E. DuenasIgnacio WistubaJulia Mendoza PerezBeatriz Sanchez EspiridionRoland L. BassettTapan M. KadiaCourtney D. DiNardoFarhad RavandiJeremy RamdialRohtesh S. MehtaAmin M. AlousiBetul OranIssa F. KhouriQaiser BashirChitra HosingMuzaffar H. QazilbashJin S. ImPartow KebriaeiPavan BachireddyJeffrey J. MolldremJeffrey L. JorgensenSa A. WangWei WANGUday PopatElizabeth J. ShpallRichard E. ChamplinHagop M. KantarjianNaval Daver

urologyhematologymedicineclinical transplantationhigh riskoncologystem cellsleukemiabone marrow transplantationmalignant blood disordersimmunologycancer treatmentcell transplantationstem cell transplantationstem-cell therapyacute myeloid leukemiamyeloid neoplasia

Cathepsin G is Broadly Expressed in Acute Myeloid Leukemia and is an Effective Immunotherapeutic Target. UNC Libraries (2024)

cancer immunotherapyeffective immunotherapeutic targetcell biologyleukemiatherapeutic targetsacute myeloid leukemiacathepsin gcellular therapyimmunotherapyimmune responsesimmunologycell deathmolecular medicinemedicinal researchhematologyhematological malignanciescancer cellspathologymyeloid neoplasia

Abstract 2995: Cross-Presented Serine Proteases as Immunotherapy Targets for Lung Cancer and Osteosarcoma. Cancer Research (2023)

lung cancercancer immunotherapyabstract 2995cell biologycancer cellsimmune checkpoint inhibitorsimmunologytherapeutic targetstumor targetingcancer discoverycross-presented serine proteasespathology

Aml Immunotherapy Using a Novel Tcrm-Based Bispecific Antibody That Targets a Leader Sequence Peptide Derived From Cathepsin G. Blood (2023)

cancer immunotherapyimmune responsescellular therapyantibody engineeringaml immunotherapycell biologyimmunotherapypeptide therapeuticsimmunologytherapeutic targetspeptidescathepsin g

Data From a Novel Hla-a*0201 Restricted Peptide Derived From Cathepsin G is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. (2023)

Mao ZhangPariya SukhumalchandraAtim A. EnyenihiLisa S. St. JohnSally A. HunsuckerElizabeth A. MittendorfAnna SergeevaKathryn RuisaardZein Al-AtrachePatricia A. RoppHaroon JakherTania Rodriguez-CruzGregory LizeeKaren Clise-DwyerSijie LuJeffrey J. MolldremGary L. GlishPaul M. ArmisteadGheath Alatrash

hematologycancer immunotherapyimmunotherapyimmunologypharmacologyhla typingacute myeloid leukemiapeptides

Data From Breast Cancer Cell Uptake of the Inflammatory Mediator Neutrophil Elastase Triggers an Anticancer Adaptive Immune Response. (2023)

immune responsescellular therapyinflammationcell biologycancer cellsbreast oncologycancer immunosurveillanceimmunologytumor microenvironmentbreast cancer

Data From Trastuzumab Increases Her2 Uptake and Cross-Presentation by Dendritic Cells. (2023)

Victor A. GallAnne V. PhilipsNa QiaoKaren Clise-DwyerAlexander A. PerakisMao ZhangGuy T. CliftonPariya SukhumalchandraQing MaSangeetha M. ReddyDihua YuJeffrey J. MolldremGeorge E. PeoplesGheath AlatrashElizabeth A. Mittendorf

immunomodulationcancer immunotherapyimmune responsesinflammationreproductive immunologyinfectious diseasesadaptive immune systemcancer cellsimmune checkpoint inhibitorsimmunotherapysystems biologyimmunologyimmunity (medicine)cancer immunosurveillancedendritic cellstrastuzumab increasescancer discoveryspecific resistance

Supplemental Figure From Trastuzumab Increases Her2 Uptake and Cross-Presentation by Dendritic Cells. (2023)

immunomodulationcancer immunotherapycancer immunosurveillancedendritic cellssupplemental figurecellular therapyimmunotherapyimmune responsesreproductive immunologyradiation oncologymolecular canceradaptive immune systemimmune checkpoint inhibitorsimmunologyimmunity (medicine)intermediate hostmedicinal researchallergyinflammationcancer cellstrastuzumab increases

1
2
3
4
5
6
10 / page

Pariya Sukhumalchandra

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hematopoietic Biology And Malignancy

NonePariya Sukhumalchandra is currently serving as a Hematopoietic Biology And Malignancy faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Pariya Sukhumalchandra

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Immunotherapy Targeting a Leader Sequence Cathepsin G-Derived Peptide. Leukemia (2025)

immune responsescellular therapyimmunotherapypeptide therapeuticsimmunologypeptide sciencepeptidesmedicinal researchleader sequence

T Cell Receptor Mimic Car T Cells Targeting Cathepsin G Signal Peptide. Leukemia (2025)

receptorsimmune responsescellular therapycell biologycell signalingmolecular immunologyimmunologycell researchsignal transductioncellular immune responses

Cathepsin G is Broadly Expressed in Acute Myeloid Leukemia and is an Effective Immunotherapeutic Target. UNC Libraries (2024)

Abstract 2995: Cross-Presented Serine Proteases as Immunotherapy Targets for Lung Cancer and Osteosarcoma. Cancer Research (2023)

lung cancercancer immunotherapyabstract 2995cell biologycancer cellsimmune checkpoint inhibitorsimmunologytherapeutic targetstumor targetingcancer discoverycross-presented serine proteasespathology

Aml Immunotherapy Using a Novel Tcrm-Based Bispecific Antibody That Targets a Leader Sequence Peptide Derived From Cathepsin G. Blood (2023)

cancer immunotherapyimmune responsescellular therapyantibody engineeringaml immunotherapycell biologyimmunotherapypeptide therapeuticsimmunologytherapeutic targetspeptidescathepsin g

Data From a Novel Hla-a*0201 Restricted Peptide Derived From Cathepsin G is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. (2023)

hematologycancer immunotherapyimmunotherapyimmunologypharmacologyhla typingacute myeloid leukemiapeptides

Data From Breast Cancer Cell Uptake of the Inflammatory Mediator Neutrophil Elastase Triggers an Anticancer Adaptive Immune Response. (2023)

immune responsescellular therapyinflammationcell biologycancer cellsbreast oncologycancer immunosurveillanceimmunologytumor microenvironmentbreast cancer

Data From Trastuzumab Increases Her2 Uptake and Cross-Presentation by Dendritic Cells. (2023)

Supplemental Figure From Trastuzumab Increases Her2 Uptake and Cross-Presentation by Dendritic Cells. (2023)

1
2
3
4
5
6
10 / page